pharmiweb.com today | 20 June 2013
AstraZeneca selects location for new global R&D centre and corporate headquarters in Cambridge, UK
AstraZeneca today announced that its new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a highly-skilled workforce of approximately 2,000.
As announced on 18 March 2013, the investment in a ÂŁ330 million facility in Cambridge is part of the companyâs move to create strategic global R&D centres in the UK, US and Sweden to improve pipeline productivity and to establish AstraZeneca as a global leader in biopharmaceutical innovation....
Pascal Soriot, Chief Executive Officer of AstraZeneca said: âCambridge competes on the global stage as a respected innovation hub for life sciences and our choice of site puts us at the heart of this important ecosystem, providing valuable collaboration opportunities. Moving to the Cambridge Biomedical Campus means our people will be able to rub shoulders with some of the worldâs best scientists and clinicians carrying out some of the worldâs leading research â thatâs a really exciting prospect. We hope that our move will contribute to the growing success of Cambridge.
âTodayâs announcement also confirms AstraZenecaâs long-standing commitment to the UK and increases the chances that the next generation of medicines will be discovered here in Britain.â
show moreshow less